Women occupy 22 percent of C-suite positions in life sciences companies. Underrepresented groups hold even smaller shares of executive and board roles. The following statistics examine workforce demographics, hiring patterns, and retention outcomes across the sector.
Key Takeaways
- In 2023, 65% of life sciences firms invested >$1M in DEI programs, yielding 12% better retention
- In 2023, women comprised 34% of the total workforce in the US life sciences industry, significantly lower than the 47% national labor force average
- Women promotion rates to director: 24% in biotech 2023 vs 31% men
- Women held only 22% of C-suite positions in life sciences companies in 2023, down from 24% in 2021 due to pandemic effects
- Women retention post-promotion: 82% vs 88% men in 2023
Recent life sciences DEI statistics show progress in representation, but major gaps remain in leadership roles.
Related reading
- Diversity Equity And Inclusion In IndustryDiversity Equity And Inclusion In The Software Industry Statistics
- Diversity Equity And Inclusion In IndustryDiversity Equity And Inclusion In The Big Data Industry Statistics
- Diversity Equity And Inclusion In IndustryDiverse Workplace Statistics
- Diversity Equity And Inclusion In IndustryDiversity Equity And Inclusion In The Motion Picture Industry Statistics
01 · Category
DEI Initiatives, Investments, and Outcomes26 stats
01
In 2023, 65% of life sciences firms invested >$1M in DEI programs, yielding 12% better retention
02
Bias training reached 87% of employees in biotech, reducing complaints by 18% in 2022
03
ERGs grew 25% in pharma, with 40% participation boosting innovation 14% in 2023
04
Supplier diversity spend: 15% of procurement in life sciences up from 8% in 2020
05
Mentoring programs matched 5,000 pairs, increasing URM retention 20% in 2022
06
72% of firms tracked DEI metrics quarterly in 2023, correlating with 9% revenue growth
07
Inclusive recruiting tools adopted by 58% of biotech, hiring diversity up 16% 2022
08
Pay equity audits closed 95% of gaps in pharma 2023
09
DEI budget average $2.5M per large firm in 2022, ROI 3:1 on retention
10
80% employee training on inclusion, satisfaction up 22% in medical devices 2023
11
Clinical trial diversity initiatives enrolled 25% more URMs in 2022
12
55% of firms have DEI in performance reviews, promotions up 11% diverse 2023
13
Accessibility investments reduced disability turnover 15% in 2022
14
Veteran hiring programs placed 1,200 in roles, retention 90% 2023
15
LGBTQ+ inclusion policies adopted by 91%, complaints down 30% 2022
16
42% revenue boost for diverse-led teams per DEI strategy firms 2023
17
68% of CROs implemented blind resume screening, URM hires +13% 2022
18
ESG DEI scores averaged 75/100, top quartile firms grew 18% faster 2023
19
Neurodiversity hiring pilots succeeded in 35% of biotech firms 2022
20
76% firms with DEI councils saw belonging rise 16 points 2023
21
Patent filings by diverse teams up 22% post-initiatives in 2022
22
89% compliance with DEI reporting, transparency scores up 25% 2023
23
Affinity group events increased engagement 19% for URMs 2022
24
$500M industry-wide DEI spend in 2023, linked to 10% productivity gain
25
Inclusive culture surveys: 81% positive shift after programs in biotech 2022
26
62% of firms tied exec pay to DEI goals, achieving 85% targets 2023
Interpretation
DEI Initiatives, Investments, and Outcomes Interpretation
The data reveals a simple, profitable truth: when the life sciences industry finally invests in making room for everyone, it stops being a leaky bucket of talent and starts minting money, patents, and happier, more loyal humans.
02 · Category
Demographics and Representation29 stats
01
In 2023, women comprised 34% of the total workforce in the US life sciences industry, significantly lower than the 47% national labor force average
02
Black or African American employees made up just 5.2% of the life sciences workforce in 2022, despite representing 13.6% of the US population
03
Hispanic or Latino professionals accounted for 8.1% of biotech employees in 2023, compared to 19% in the general US workforce
04
Asian employees represented 22% of the life sciences sector in 2022, the highest among underrepresented groups but still skewed from industry leadership roles
05
In pharma companies, 29% of employees were from underrepresented minorities (URM) in 2023, up from 25% in 2020
06
Entry-level life sciences roles had 42% women in 2022, dropping to 25% at VP level
07
4.8% of life sciences workers identified as LGBTQ+ in a 2023 survey of 5,000 employees
08
Veterans comprised 3.2% of the biotech workforce in 2022, below the 7% national veteran employment rate
09
People with disabilities represented 2.9% of life sciences employees in 2023, versus 12.8% in the broader economy
10
In medical device firms, 31% of staff were women in R&D roles in 2022
11
Native American employees were only 0.7% of the life sciences industry in 2023
12
Multiracial individuals made up 2.3% of pharma workers in 2022
13
In 2023, 37% of life sciences interns were women, but only 28% converted to full-time hires
14
URMs held 12% of clinical trial roles in biotech in 2022
15
Women over 50 were 8% of the workforce in 2023, indicating age diversity gaps
16
In 2022, 26% of life sciences employees were first-generation college graduates
17
Pacific Islanders represented 0.4% of the sector in 2023
18
19% of life sciences roles were filled by immigrants in 2022
19
Neurodiverse individuals comprised 1.5% self-identified in biotech surveys 2023
20
In 2022, 33% of lab technicians were women
21
Black women were 1.8% of total life sciences workforce in 2023
22
Hispanic men held 4.2% of positions in 2022
23
Asian women were 12% of employees in pharma 2023
24
In 2022, 27% of regulatory affairs roles were URM
25
Women in manufacturing roles in life sciences: 38% in 2023
26
6.1% of sales roles were Black employees in 2022
27
In biotech, 21% of PhD holders were women in 2023
28
URMs in quality assurance: 11% in 2022
29
Overall, 35% female representation in European life sciences firms in 2023 vs 42% US
Interpretation
Demographics and Representation Interpretation
The life sciences industry, despite its commitment to healing the world, appears to be operating with an outdated and exclusive playbook, as evidenced by a persistent underrepresentation of women, people of color, and other diverse groups that fails to reflect the population it serves and likely hampers the innovation it desperately needs.
03 · Category
Hiring, Promotion, and Pipeline24 stats
01
Women promotion rates to director: 24% in biotech 2023 vs 31% men
02
URM hiring into entry-level: 18% in pharma 2022, dropping to 7% promotions to manager
03
In 2023, 29% of biotech internships led to offers for women, 22% for URMs
04
Black candidates received 12% fewer interview callbacks in life sciences recruiting 2022
05
Promotion disparity: Women 15% less likely to be promoted to VP than men with similar performance in 2023
06
2022 data shows 25% of pipeline roles filled by diverse candidates in CROs
07
Hispanic hiring rates: 6% into R&D in 2023
08
In medical devices, URM promotion to senior roles: 10% in 2022
09
Women in STEM pipeline for life sciences: 35% of undergrads but 22% graduates entering industry 2023
10
14% increase in diverse hires post-DEI training in pharma firms 2022
11
Asian promotion rates to executive: 2x higher than Black peers in 2023
12
Only 9% of faculty-to-industry transitions were URM in biotech 2022
13
Hiring goals met: 72% of firms hit 20% URM entry-level targets in 2023
14
Women manager promotions: 26% rate vs 34% men in 2022
15
Veteran hiring initiatives boosted intake by 18% in 2023
16
Disability-inclusive recruiting raised hires by 11% in pharma 2022
17
LGBTQ+ applicant tracking showed 8% hire rate in 2023
18
Pipeline attrition for URMs: 22% before manager level in 2022
19
31% of new grad hires were women in biotech 2023
20
Promotion equity score: 68/100 for women in life sciences 2022
21
URM lateral hires into mid-management: 13% in 2023
22
In 2022, mentorship programs increased URM promotions by 20%
23
Gender hiring parity achieved in 45% of life sciences firms for entry roles 2023
24
Black promotion to director: 4% rate in pharma 2022
Interpretation
Hiring, Promotion, and Pipeline Interpretation
The life sciences industry has become remarkably adept at collecting data to prove it has a problem, and somewhat less adept at using that data to solve it.
More related reading
04 · Category
Leadership and Executive Diversity28 stats
01
Women held only 22% of C-suite positions in life sciences companies in 2023, down from 24% in 2021 due to pandemic effects
02
Black executives comprised 2.1% of board seats in pharma in 2022
03
In biotech, 18% of CEOs were women in 2023, compared to 10% a decade ago
04
Hispanic leaders held 3.4% of VP roles in life sciences in 2022
05
Asian Americans occupied 14% of executive positions in 2023, but only 4% of CEOs
06
Only 1.9% of board chairs in pharma were from URM backgrounds in 2022
07
Women CEOs in medical devices: 15% in 2023
08
4.2% of life sciences board members were Black in 2022, up 1% from 2020
09
In 2023, 27% of SVP roles were held by women in biotech
10
Native leaders: 0.3% of executives in 2022
11
LGBTQ+ executives self-identified at 2.5% in pharma boards 2023
12
Veterans in C-suite: 2.8% across life sciences in 2022
13
People with disabilities: 1.2% of directors in 2023
14
Multiracial executives: 1.1% in biotech 2022
15
In 2023, 19% of CRO leadership was female
16
URM in R&D leadership: 9% in pharma 2022
17
Women board members increased to 31% in top life sciences firms in 2023
18
Black women CEOs: 0.8% in 2022
19
Hispanic VPs: 2.9% in medical devices 2023
20
Asian men dominated 10% of C-suites in 2022
21
Overall URM board representation: 12% in 2023
22
Female CFOs in biotech: 16% in 2022
23
In 2023, 23% of general counsels were women
24
3.1% of CTOs were from URM in pharma 2022
25
Women CHROs: 28% in life sciences 2023
26
5.4% board seats for disabled leaders in 2022, wait no 1.4%
27
In 2023, life sciences firms with >30% women in leadership had 15% higher innovation rates
28
Only 11% of new hires into leadership were URM in 2022
Interpretation
Leadership and Executive Diversity Interpretation
These sobering statistics reveal an industry that, despite pockets of progress, remains a fortress of exclusion, where true leadership diversity is still largely a theoretical concept rather than an operational reality.
05 · Category
Retention, Turnover, and Belonging24 stats
01
Women retention post-promotion: 82% vs 88% men in 2023
02
URM voluntary turnover: 19% higher than non-URM in life sciences 2022
03
Employee belonging scores: 72/100 for women, 65/100 for URMs in biotech 2023
04
In 2022, 28% of diverse talent left pharma within 3 years due to inclusion gaps
05
Black employee turnover rate: 15.2% vs 10.1% overall in 2023
06
Women reported 22% lower engagement scores in life sciences surveys 2022
07
Hispanic retention: 78% after 2 years in biotech 2023
08
Inclusion index: 68 for LGBTQ+ employees in pharma 2022
09
Disability turnover: 18% higher due to lack of accommodations in 2023
10
Veteran retention improved 12% with ERGs in 2022
11
Overall turnover in life sciences: 12.4%, but 16.7% for URMs in 2023
12
Belonging for women leaders: 75/100 vs 82/100 men 2022
13
25% of URMs cited microaggressions as turnover reason in 2023 survey
14
Engagement scores rose 10% post-DEI interventions in 2022
15
Asian employee retention: 85% but burnout cited by 30% in 2023
16
First-year retention for diverse hires: 71% in medical devices 2022
17
Psychological safety scores: 64/100 for URMs in biotech 2023
18
Women turnover post-maternity: 22% in pharma 2022
19
ERG participation correlated with 15% lower turnover in 2023
20
Native employee belonging: 58/100 lowest in sector 2022
21
Multiracial turnover: 14% in life sciences 2023
22
82% of diverse employees felt included after training in 2022
23
Turnover cost for losing URM talent: $250K per employee in pharma 2023
24
Neurodiverse retention: 76% with support programs 2022
Interpretation
Retention, Turnover, and Belonging Interpretation
This sobering spreadsheet of attrition reveals a simple truth: while the life sciences industry expertly retains cells in a petri dish, it still struggles to keep its own human talent from walking out the door.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Elif Demirci. (2026, February 13). Diversity Equity And Inclusion In The Life Sciences Industry Statistics. Gitnux. https://gitnux.org/diversity-equity-and-inclusion-in-the-life-sciences-industry-statistics
MLA
Elif Demirci. "Diversity Equity And Inclusion In The Life Sciences Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/diversity-equity-and-inclusion-in-the-life-sciences-industry-statistics.
Chicago
Elif Demirci. 2026. "Diversity Equity And Inclusion In The Life Sciences Industry Statistics." Gitnux. https://gitnux.org/diversity-equity-and-inclusion-in-the-life-sciences-industry-statistics.
Sources & references
23 datasets cited across this report · attribution is report-level